Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Ansell

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Leukemia & Lymphoma|February 3, 2022
Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experienceMegan Melody, Sangeetha Gandhi, Hollie Saunders, et al.
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
Science Translational Medicine|March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphomaBart Burington, Peng Yue, Xiaoyan Shi, et al.
American Journal of Hematology|January 11, 2023
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Michael A Spinner, Kevin David, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2018
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin LymphomaMargaretha G M Roemer, Robert A Redd, Fathima Zumla Cader, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2020
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020Neha Mehta-Shah, Steven M Horwitz, Stephen Ansell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021Steven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2022
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in OncologySteven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Blood Advances|March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphomaReid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Blood|June 2, 2022
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory CommitteeElias Campo, Elaine S Jaffe, James R Cook, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Leukemia & Lymphoma|February 3, 2022
Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experienceMegan Melody, Sangeetha Gandhi, Hollie Saunders, et al.
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
Science Translational Medicine|March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphomaBart Burington, Peng Yue, Xiaoyan Shi, et al.
American Journal of Hematology|January 11, 2023
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphomaSanjal H Desai, Michael A Spinner, Kevin David, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2018
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin LymphomaMargaretha G M Roemer, Robert A Redd, Fathima Zumla Cader, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2020
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020Neha Mehta-Shah, Steven M Horwitz, Stephen Ansell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021Steven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2022
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in OncologySteven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Blood Advances|March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphomaReid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Blood|June 2, 2022
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory CommitteeElias Campo, Elaine S Jaffe, James R Cook, et al.
Pageof 4